Sunny Pharmtech Inc. 祥翊製藥股份有限公司’s generic drug injectable, Cyclophosphamide (CPA-I), successfully dispatched its inaugural shipment on 30th November, targeting a $100 million market. This FDA-approved CPA-I, granted in late October, is used in treating various types of cancers.
Dive deeper: https://lnkd.in/dk3gT_D7
Stay tuned to #Globalbio on LinkedIn for the latest updates!
#SunnyPharmtech #FDAapproval #GenericDrugs #cancertreatment
Sunny Pharmtech Inc.’s CPA-I successfully dispatched its inaugural shipment on 30th November
撰文GlobalBio & Investment
日期2023-12-31
Sunny Pharmtech Inc.’s CPA-I successfully dispatched its inaugural shipment on 30th November